Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

Parametric Survival Analysis: Weibull and Exponential Methods

Parametric Survival Analysis: Weibull and Exponential Methods

Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

Kaplan-Meier Approach

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

Pharmacokinetic Models: Comparison and Selection Criterion

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Causal inference and digital twins: a roadmap for the future of clinical trials.

NPJ digital medicine·2026

Same author

PS-SAM: propensity-score-integrated self-adapting mixture prior to dynamically and efficiently borrow information from historical data.

Journal of biopharmaceutical statistics·2025

Same author

Human bone ultrastructure in 3D: Multimodal correlative study combining nanoscale X-ray computed tomography and quantitative polarized Raman spectroscopy.

Acta biomaterialia·2025

Same author

A Bayesian phase II proof-of-concept design for clinical trials with longitudinal endpoints.

Statistics in medicine·2023

Same author

Composition and micromechanical properties of the femoral neck compact bone in relation to patient age, sex and hip fracture occurrence.

Bone·2023

Same author

Prevention strategies and modifiable risk factors for sport-related concussions and head impacts: a systematic review and meta-analysis.

British journal of sports medicine·2023

Search research articles

Related Experiment Videos

A Bayesian case study in oncology Phase I combination dose-finding using logistic regression with covariates.

Stuart Bailey¹, Beat Neuenschwander, Glen Laird

¹Novartis Pharma AG, Basel, Switzerland. stuart.bailey@novartis.com

Journal of Biopharmaceutical Statistics

|April 23, 2009

Summary

This study introduces a flexible Bayesian method for determining the maximum tolerated dose (MTD) of cancer drugs. It provides clear dose recommendations by analyzing the probability of dose-limiting toxicities (DLT).

Related Experiment Videos

Area of Science:

Oncology
Biostatistics
Clinical Trial Design

Background:

Determining the maximum tolerated dose (MTD) is crucial for early-phase cancer clinical trials.
Traditional methods for MTD estimation can be inflexible and lack transparency.
Integrating covariates can improve the precision of MTD estimation.

Purpose of the Study:

To present a novel Bayesian approach for MTD determination.
To demonstrate the flexibility of the Bayesian method in incorporating covariates.
To provide transparent dose recommendations based on comprehensive inferential summaries.

Main Methods:

A Bayesian statistical framework was employed for dose-finding.
The method allows for the inclusion of patient-specific covariates.
Probabilities of dose-limiting toxicities (DLT) were comprehensively summarized for inferential purposes.

Main Results:

The Bayesian approach facilitated transparent dose recommendations.
Covariates were successfully integrated into the MTD estimation process.
A case study involving a Phase I trial of nilotinib and imatinib demonstrated the method's application.

Conclusions:

The presented Bayesian approach offers a flexible and transparent method for MTD determination in oncology trials.
The method enhances decision-making by providing clear inferential summaries of DLT probabilities.
The case study highlights the practical utility and interpretability of the approach using within- and end-of-study data.